Results from Kadcyla Phase III Trial, TH3RESA, and the impact this will have on the breast cancer market
Insight into BioMarin’s PARP inhibitor BMN-763 and it’s effectiveness for BRCA mutation-positive metastatic breast cancer patients
Find out the likelihood of trebananib/paclitaxel regimen being approved
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: